Cargando…

Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients

BACKGROUND: Clopidogrel is an antiplatelet drug used in the treatment of ischemic stroke. Safety and efficacy of clopidogrel has been confirmed in CAPRIE, PRoFESS trials. However, these studies focused on patients aged less than 75 years. CYP2C19 polymorphisms resulted in individual differences in c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Changqing, Jia, Weihua, Li, Jian, Li, Fangfei, Ma, Jing, Zhou, Lichun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941922/ https://www.ncbi.nlm.nih.gov/pubmed/33685396 http://dx.doi.org/10.1186/s12883-021-02127-6

Ejemplares similares

Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients
por: Zhuo, Zhong-ling, et al.
Publicado: (2018)

Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China
por: Su, Qiang, et al.
Publicado: (2019)

Relationship between CYP2C19 Polymorphism and Clopidogrel Resistance in Patients with Coronary Heart Disease and Ischemic Stroke in China
por: Chang, Rong, et al.
Publicado: (2022)

Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia
por: Alhazzani, Adel A., et al.
Publicado: (2017)

Comment on “Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients”
por: Wang, Bin, et al.
Publicado: (2018)

The correlation between recurrent risk and CYP2C19 gene polymorphisms in patients with ischemic stroke treated with clopidogrel for prevention
por: Liu, Guohua, et al.
Publicado: (2020)

The clinical impact of CYP2C19 *2 and *3 polymorphism on Clopidogrel and cost analysis
por: Meman A, Al, et al.
Publicado: (2014)

Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke
por: Rath, Charlotte Lützhøft, et al.
Publicado: (2020)

Impacts of CYP2C19 Polymorphism and Clopidogrel Dosing on in-Stent Restenosis: A Retrospective Cohort Study in Chinese Patients
por: Zhang, Min, et al.
Publicado: (2020)

Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia
por: Zhu, Wen-Yao, et al.
Publicado: (2016)

The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
por: Pettersen, Alf-Aage R, et al.
Publicado: (2011)

CYP2C19 polymorphisms and lipoproteins associated with clopidogrel resistance in children with Kawasaki disease in China: A prospective study
por: Zhang, Mingming, et al.
Publicado: (2022)

Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis
por: Yao, Jia-Chen, et al.
Publicado: (2018)

CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors
por: Sukasem, Chonlaphat, et al.
Publicado: (2013)

Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients
por: Marchini, J.F.M., et al.
Publicado: (2017)

Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism
por: Afzal, Ashwad, et al.
Publicado: (2016)

Correlation study of CYP2C19 gene polymorphism and clopidogrel resistance in Han Chinese patients with cerebral infarction in Guizhou region
por: Shi, Guo-Xian, et al.
Publicado: (2021)

CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt
por: Shawky, Ahmed, et al.
Publicado: (2023)

CYP2C19 Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study
por: McDonough, Caitrin W, et al.
Publicado: (2015)

ABCB1 C3435T and CYP2C19*2 polymorphisms in a Palestinian and Turkish population: A pharmacogenetic perspective to clopidogrel
por: Nassar, Suheir, et al.
Publicado: (2014)

The Dynamic Effect of Non-CYP3A4-Metabolized and CYP3A4-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction
por: Shi, Hong Ting, et al.
Publicado: (2021)

Should CYP2C19 Genotyping Be Recommended as a Straight Forward Approach to Optimize Clopidogrel Utilization in Patients with Ischemic Stroke Complicated by Type 2 Diabetes Mellitus?
por: Sun, Jialin, et al.
Publicado: (2020)

Analysis of CYP2C19 gene polymorphism and influencing factors of pharmacological response of clopidogrel in patients with cerebral infarction in Zhejiang, China
por: Mo, Yijun, et al.
Publicado: (2023)

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
por: Brown, Sherry-Ann, et al.
Publicado: (2018)

CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
por: Mirabbasi, Seyed abbas, et al.
Publicado: (2017)

Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example
por: Kisor, David F, et al.
Publicado: (2021)

Prevalence of CYP2C9 and CYP2C19 variants and the impact on clopidogrel efficacy in patients having CYPC19*2 variant
por: Mehta, Meha P., et al.
Publicado: (2023)

Variants in clopidogrel-relevant genes and early neurological deterioration in ischemic stroke patients receiving clopidogrel
por: Yi, Xingyang, et al.
Publicado: (2020)

The impact of CYP2C19 *2 and *3 polymorphism on clopidogrel response following coronary stenting in Saudi patients with acute coronary syndrome
por: H, Khalaf, et al.
Publicado: (2014)

Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults
por: Sridharan, Kannan, et al.
Publicado: (2016)

Effectiveness and safety of high dose clopidogrel plus aspirin in ischemic stroke patients with the single CYP2C19 loss-of-function allele: a randomized trial
por: Wu, Hongliang, et al.
Publicado: (2020)

Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack
por: Li, Zixiao, et al.
Publicado: (2016)

Baseline P2Y12 reactivity, kidney function, and CYP2C19 genotype determine clopidogrel responsiveness in acute stroke
por: Lee, Yi-Chung, et al.
Publicado: (2023)

Effect of 20 mg/day Atorvastatin: Recurrent Stroke Survey in Chinese Ischemic Stroke Patients with Prior Intracranial Hemorrhage
por: Jia, Weihua, et al.
Publicado: (2013)

Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice
por: Russmann, Stefan, et al.
Publicado: (2020)

Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients
por: Ahmed, Sagheer, et al.
Publicado: (2022)

Genetic Testing for CYP450 Polymorphisms to Predict Response to Clopidogrel: current evidence and test availability: Application: Pharmacogenomics
por: Ned, Renée M.
Publicado: (2010)

Influence of CYP450 Enzymes and ABCB1 Polymorphisms on Clopidogrel Response in Moroccan Patients with Acute Coronary Syndromes
por: Mouhrach, Ismail, et al.
Publicado: (2023)

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
por: Bauer, Tim, et al.
Publicado: (2011)

Comparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carrying CYP2C19 loss of function allele
por: Qian, Wenwen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9eapjuard4b8tcuj40j9eggsfe